Evidence map›Paper›PMID 41750257›Full record

ReviewBiomolecules2026

NLRP3 Inflammasome Role and NLRP3 Inhibitors in Sensorineural Hearing Loss.

Mireia Toledano-Pinedo, José Marco-Contelles, Alexey V Dobrydnev

Abstract readReview
In one paragraph

Review in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mireia Toledano-PinedoLaboratory of Medicinal Chemistry, Institute of General Organic Chemistry (CSIC), C/Juan de la Cierva 3, 28006 Madrid, Spain.
José Marco-ContellesLaboratory of Medicinal Chemistry, Institute of General Organic Chemistry (CSIC), C/Juan de la Cierva 3, 28006 Madrid, Spain.
Alexey V DobrydnevChemistry Department, Taras Shevchenko National University of Kyiv, Volodymyrska Street 60, 01033 Kyiv, Ukraine.ORCID 0000-0001-7628-0465

Funding

CIBERER ACCI 2023
6 · The paper itself

Abstract

Herein, we will review the function of the NLRP3 inflammasome in hearing loss (HL), summarize the most significant experimental results described in recent years, describe the biological mechanisms involved in the role of NLRP3 inflammasome in HL, and highlight some of the most promising small NLRP3 inhibitors for its clinical therapy, showing excellent pharmacological effects and good pharmacodynamic/pharmacokinetic profiles.

Indexed as

Hearing Loss, SensorineuralInflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinAnimalsHumansInflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinNLRP3 protein, humananakinracanakinumabcryopyrin-associated periodic syndromesdeafnesshearing lossinflammasomeMCC950NLRP3oridoninpiceatannol

Identifiers

PMID41750257
PMCPMC12938068

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.